ReShape Lifesciences

ReShape Online Institute
Customer Service: 1-844-937-7374




Events and Presentations


Press Releases


SEC Filings


Stock Information


Analyst Coverage




Corporate Governance


Investor FAQs


Annual Reports, Proxy Statements, and Supplemental Financial Info


Email Alerts


For investor inquiries, please contact:

Investor Contact:
Scott Youngstrom



ReShape Lifesciences is a medical device company focused on technology to treat obesity and metabolic diseases. vBloc® Neurometabolic Therapy, delivered by an FDA-approved pacemaker-like device called the vBloc System, is designed to help patients with a 35-45 Body Mass Index (BMI) feel full and eat less by intermittently blocking hunger signals on the vagus nerve. The FDA-approved ReShape® Integrated Dual Balloon System involves a non-surgical weight loss procedure that uses advanced balloon technology designed to take up room in the stomach to help people with a 30-40 Body BMI, and at least one co-morbidity, lose weight. The Gastric Vest™ System is an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery, and is intended to enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy.

ReShape Lifesciences was incorporated in Minnesota in December 2002 under the name Beta Medical, Inc. In 2003, the Company changed its name to EnteroMedics Inc. and in 2004 reincorporated in Delaware. EnteroMedics began trading on the NASDAQ Stock Market on November 15, 2007.   The Company acquired ReShape Medical in October 2017 and subsequently changed the Company name to ReShape Lifesciences.  The Company trades on the NASDAQ today under the ticker symbol RSLS.

ReShape Lifesciences (NASDAQ: RSLS) 4:00 PM ET on Mar 23, 2018
Last Price Change Open Day High 52-Week High
0.00  down   (0.050%) 1.41 1.45 6.48
Volume Previous Close Day Low 52-Week Low
119,243 1.41 1.36 1.23

View all »Events & Presentations

Apr 2, 2018 at 4:30 PM ET
RSLS Fourth Quarter 2017 Earnings Call

View all »Recent Releases

Mar 20, 2018
ReShape Lifesciences Announces Update on Integration Efforts and Reschedules Fourth Quarter and Full Year 2017 Conference Call to April 2, 2018

Mar 16, 2018
ReShape vBloc to be Featured at the Bariatric Metabolic Surgery Standardization World Consensus Meeting

Forward looking statement

This website contains forward-looking statements about ReShape Lifesciences . Our actual results could differ materially from those discussed due to known and unknown risks, uncertainties and other factors including our limited history of operations; our losses since inception and for the foreseeable future; our lack of commercial sales experience with our Maestro® Rechargeable System for the treatment of obesity in the United States or in any foreign market other than Australia and the European Community; our ability to comply with the Nasdaq continued listing requirements; our ability to commercialize our Maestro System; our dependence on third parties to initiate and perform our clinical trials; the need to obtain regulatory approval for any modifications to our Maestro System; physician adoption of our Maestro System and vBloc® Neurometabolic Therapy; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; international commercialization and operation; our ability to attract and retain management and other personnel and to manage our growth effectively; potential product liability claims; potential healthcare fraud and abuse claims; healthcare legislative reform; and our ability to obtain and maintain intellectual property protection for our technology and products. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission, particularly those factors identified as "risk factors" in the annual report on Form 10-K filed March 28, 2016. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.




*Not available for sale in the United States.